NRX Pharmaceuticals, Inc. (NRXP) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

12/25

Growth 2 Margin 1 Expansion 3 Platform 4 Financial 2

latest quarter score

Earnings Reports

12
NRx Pharmaceuticals (NRXP) Q2 2026: $22M Raise Fuels Ketamine Launch and Expands Depression Treatment Pipeline
August 18, 2026
9
BitDigital (NRXP) Q1 2026: WhiteFiber Stake Hits $322M as Mining Shrinks to 13% of Revenue
May 18, 2026
11
NRXP Q4 2025: R&D Spend Down $2.4M as Three Drug Approval Paths Converge
March 24, 2026
11
NRXP Q3 2025: Hope Clinics Pipeline Adds $20M Potential, Accelerating Neuropsychiatry Shift
November 17, 2025
7
NRXP Q2 2025: Operating Loss Down 47% as Regulatory Milestones Unlock Ketamine Market Upside
August 20, 2025
15
NRx Pharmaceuticals (NRXP) Q1 2025: $10.3M Clinic Acquisition Capital Accelerates HOPE Therapeutics Network Expansion
May 15, 2025
10
NRx Pharmaceuticals (NRXP) Q4 2024: $300M Ketamine Licensing Term Sheet Signals Commercial Inflection
March 17, 2025

Browse all companies